Table 2.
Drug classes a | Cases | Proportion |
---|---|---|
NRTIs | 1 | 0.21% |
NNRTIs | 12 | 2.47% |
Dual resistance to NRTIs and NNRTIs | 2 | 0.41% |
Susceptible | 471 | 96.91% |
Total | 486 | 100.00% |
Note: aNRTIs nucleoside reverse transcriptase inhibitors, NNRTIs non-nucleoside reverse transcriptase inhibitors; the drug classes were exclusive of each other in the study population